Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs.
Masimo to Present in the Jefferies London Healthcare Conference
Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at A replay of the webcast will be available following the live presentation.
Merck to Participate in the Jefferies London Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and head of oncology,
Wave Life Sciences to Present at Jefferies London Healthcare Conference
A live webcast of this presentation can be accessed by visiting “Investor Events” on the Investor Relations section of the Wave Life Sciences website: A replay of this presentation will be archived and available on the site for a limited time following the event.
Korro to Present at the Jefferies London Healthcare Conference
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit.
Aurinia to Participate in Jefferies London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies,
Structure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy Recommendation
BMO Capital analyst Evan Seigerman has reiterated their bullish stance on GPCR stock, giving a Buy rating on November 5. Evan Seigerman has ...
Yahoo Finance22d
GPCR drugmaker Septerna amasses $288M in IPO
Septerna’s lead drug candidate, dubbed SEP-786, targets a GPCR implicated in hypoparathyroidism. It entered human testing last month, and the company expects to report data in the middle of 2025.
MedCity News21d
Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs
PTH1R is a G protein coupled-receptor (GPCR), part of a family of receptors that regulate a wide range of physiological processes. The role of these receptors in both health and disease is known ...
Insider Monkey1mon
Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes
In this article, we are going to take a look at where Structure Therapeutics (NASDAQ:GPCR) stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk ...
Nature9d
The next era for GPCR-focused biopharma
Heptares was founded in 2007 on this technology, and Nxera is building on this long history and experience to develop the next generation of GPCR-targeted drugs — and beyond. With more than 800 ...
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei ...
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?
In this article, we will look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ranks among the best young stocks to buy ...
pharmaphorum7d
The future of AI drug discovery & development in immunology and GPCR research
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. A mere six months ago Verily ...
FierceBiotech25d
Septerna plans $158M IPO to fund clinical readouts for GPCR pipeline
Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...
Nature7d
Selecting a cyclic AMP kit for assaying GPCR target activation
Classically, the GPCR signaling pathway is considered to be a three-component system that involves a seven-transmembrane-domain receptor, a trimeric G-protein complex (Gα, Gβ, Gγ) and an effector.